JP6218152B2 - 内耳細胞誘導方法 - Google Patents
内耳細胞誘導方法 Download PDFInfo
- Publication number
- JP6218152B2 JP6218152B2 JP2015098423A JP2015098423A JP6218152B2 JP 6218152 B2 JP6218152 B2 JP 6218152B2 JP 2015098423 A JP2015098423 A JP 2015098423A JP 2015098423 A JP2015098423 A JP 2015098423A JP 6218152 B2 JP6218152 B2 JP 6218152B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- inner ear
- culturing
- stem cells
- bfgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003027 ear inner Anatomy 0.000 title claims description 72
- 238000000034 method Methods 0.000 title claims description 51
- 230000006698 induction Effects 0.000 title claims description 27
- 210000004027 cell Anatomy 0.000 claims description 182
- 210000000130 stem cell Anatomy 0.000 claims description 50
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 41
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 41
- 238000012258 culturing Methods 0.000 claims description 31
- 230000002792 vascular Effects 0.000 claims description 25
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 20
- 230000001939 inductive effect Effects 0.000 claims description 19
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 17
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 17
- 210000002768 hair cell Anatomy 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 16
- 238000004114 suspension culture Methods 0.000 claims description 16
- 239000003102 growth factor Substances 0.000 claims description 15
- 239000012679 serum free medium Substances 0.000 claims description 14
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 13
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims description 13
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 13
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 claims description 13
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 claims description 13
- 102000011384 Pendrin Human genes 0.000 claims description 13
- 108050001616 Pendrin Proteins 0.000 claims description 13
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims description 13
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 11
- 208000005400 Synovial Cyst Diseases 0.000 claims description 11
- 229960002897 heparin Drugs 0.000 claims description 11
- 229920000669 heparin Polymers 0.000 claims description 11
- 230000001953 sensory effect Effects 0.000 claims description 11
- 102100031361 Fibroblast growth factor 20 Human genes 0.000 claims description 9
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 claims description 9
- 101000846532 Homo sapiens Fibroblast growth factor 20 Proteins 0.000 claims description 9
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 9
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 7
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 claims description 7
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 7
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 claims description 7
- 210000000270 basal cell Anatomy 0.000 claims description 7
- 210000000981 epithelium Anatomy 0.000 claims description 6
- -1 Wnt3a Proteins 0.000 claims description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 4
- 210000002569 neuron Anatomy 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 210000004498 neuroglial cell Anatomy 0.000 claims description 3
- 210000005167 vascular cell Anatomy 0.000 claims description 3
- 239000011435 rock Substances 0.000 claims 2
- 239000002609 medium Substances 0.000 description 48
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 25
- 238000010186 staining Methods 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 11
- 102000011383 Prestin Human genes 0.000 description 7
- 108050001617 Prestin Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 102000055974 Connexin 26 Human genes 0.000 description 5
- 108010069156 Connexin 26 Proteins 0.000 description 5
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 5
- 102000003505 Myosin Human genes 0.000 description 5
- 108060008487 Myosin Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 108091006112 ATPases Proteins 0.000 description 4
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 4
- 102100031809 Espin Human genes 0.000 description 4
- 101710118108 Espin Proteins 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 4
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 4
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 4
- 101000653635 Homo sapiens T-box transcription factor TBX18 Proteins 0.000 description 4
- 102100029848 T-box transcription factor TBX18 Human genes 0.000 description 4
- 108010065472 Vimentin Proteins 0.000 description 4
- 102000013127 Vimentin Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000014823 calbindin Human genes 0.000 description 4
- 108060001061 calbindin Proteins 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 210000000630 fibrocyte Anatomy 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000005048 vimentin Anatomy 0.000 description 4
- 102000004888 Aquaporin 1 Human genes 0.000 description 3
- 108090001004 Aquaporin 1 Proteins 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 101000745406 Homo sapiens Ketimine reductase mu-crystallin Proteins 0.000 description 3
- 101000572950 Homo sapiens POU domain, class 3, transcription factor 4 Proteins 0.000 description 3
- 102100039386 Ketimine reductase mu-crystallin Human genes 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 3
- 108091006620 SLC12A2 Proteins 0.000 description 3
- 102100034243 Solute carrier family 12 member 2 Human genes 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 102000028861 calmodulin binding Human genes 0.000 description 3
- 108091000084 calmodulin binding Proteins 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102000010970 Connexin Human genes 0.000 description 2
- 108050001175 Connexin Proteins 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000025611 cell-substrate adhesion Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000012137 double-staining Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 244000182625 Dictamnus albus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100026466 POU domain, class 2, transcription factor 3 Human genes 0.000 description 1
- 101710084413 POU domain, class 2, transcription factor 3 Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 238000013210 evaluation model Methods 0.000 description 1
- 229960002435 fasudil Drugs 0.000 description 1
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 108010053226 substrate adhesion molecules Proteins 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015098423A JP6218152B2 (ja) | 2014-05-13 | 2015-05-13 | 内耳細胞誘導方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014100017 | 2014-05-13 | ||
| JP2014100017 | 2014-05-13 | ||
| JP2015098423A JP6218152B2 (ja) | 2014-05-13 | 2015-05-13 | 内耳細胞誘導方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015231365A JP2015231365A (ja) | 2015-12-24 |
| JP2015231365A5 JP2015231365A5 (enrdf_load_stackoverflow) | 2017-06-01 |
| JP6218152B2 true JP6218152B2 (ja) | 2017-10-25 |
Family
ID=54933292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015098423A Active JP6218152B2 (ja) | 2014-05-13 | 2015-05-13 | 内耳細胞誘導方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6218152B2 (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023033149A1 (ja) | 2021-09-03 | 2023-03-09 | 学校法人北里研究所 | 内耳血管条辺縁細胞の製造方法、薬剤の評価方法、及び薬剤評価用細胞培養物 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6850025B2 (ja) * | 2016-02-22 | 2021-03-31 | 学校法人順天堂 | 内耳細胞の製造法 |
| JP2023106639A (ja) * | 2020-06-09 | 2023-08-02 | 株式会社オトリンク | 内耳前駆細胞の製造方法、内耳有毛細胞の製造方法、薬剤の評価方法、及び内耳細胞分化誘導用組成物 |
| JP2023106640A (ja) * | 2020-06-09 | 2023-08-02 | 株式会社オトリンク | 内耳有毛細胞の製造方法、薬剤の評価方法、及び細胞分化誘導用組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2464723B1 (en) * | 2009-08-12 | 2016-06-22 | Kyoto University | Method for inducing differentiation of pluripotent stem cells into neural precursor cells |
| US9624468B2 (en) * | 2012-05-04 | 2017-04-18 | Indiana University Research & Technology Corporation | Methods for generating the inner ear and other cranial placode-derived tissues using pluripotent stem cells |
| WO2013187416A1 (ja) * | 2012-06-12 | 2013-12-19 | 学校法人 慶應義塾 | 神経系分化に適したiPS細胞の増幅方法、及び神経幹細胞の誘導方法 |
-
2015
- 2015-05-13 JP JP2015098423A patent/JP6218152B2/ja active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023033149A1 (ja) | 2021-09-03 | 2023-03-09 | 学校法人北里研究所 | 内耳血管条辺縁細胞の製造方法、薬剤の評価方法、及び薬剤評価用細胞培養物 |
| EP4397750A4 (en) * | 2021-09-03 | 2025-08-06 | The Kitasato Inst | METHOD FOR PRODUCING MARGINAL CELLS OF THE VASCULAR STRIA OF THE INNER EAR, METHOD FOR EVALUATING A CHEMICAL AGENT, AND CELL CULTURE FOR EVALUATING A CHEMICAL AGENT |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015231365A (ja) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kwok et al. | Scalable stirred suspension culture for the generation of billions of human induced pluripotent stem cells using single‐use bioreactors | |
| Fonoudi et al. | A universal and robust integrated platform for the scalable production of human cardiomyocytes from pluripotent stem cells | |
| KR101837080B1 (ko) | 마이크로-캐리어 상의 만능 줄기 세포 배양 | |
| Hookway et al. | Aggregate formation and suspension culture of human pluripotent stem cells and differentiated progeny | |
| Lewandowski et al. | Techniques for the induction of human pluripotent stem cell differentiation towards cardiomyocytes | |
| DK2838992T3 (en) | Maintaining differentiated cells with laminins | |
| JP6218152B2 (ja) | 内耳細胞誘導方法 | |
| Hook et al. | Non-immortalized human neural stem (NS) cells as a scalable platform for cellular assays | |
| Kumar et al. | Generation of an expandable intermediate mesoderm restricted progenitor cell line from human pluripotent stem cells | |
| JP2019022509A (ja) | 幹細胞および幹細胞に由来する細胞を単離するための、接着シグネチャーベースの方法 | |
| Sambo et al. | Transient treatment of human pluripotent stem cells with DMSO to promote differentiation | |
| JP7198524B2 (ja) | スフェロイドの製造方法および多能性幹細胞マーカーを発現させる方法 | |
| Liu et al. | Microfibrous carriers for integrated expansion and neural differentiation of embryonic stem cells in suspension bioreactor | |
| WO2022188395A1 (zh) | 一种多能干细胞的培养方法 | |
| WO2021251418A1 (ja) | 内耳前駆細胞の製造方法、内耳有毛細胞の製造方法、薬剤の評価方法、及び内耳細胞分化誘導用組成物 | |
| Lee et al. | Clump-passaging-based efficient 3D culture of human pluripotent stem cells under chemically defined conditions | |
| CN116983479B (zh) | 一种利用3d打印制备人工血管实现人脑类器官血管化的方法 | |
| WO2023033149A1 (ja) | 内耳血管条辺縁細胞の製造方法、薬剤の評価方法、及び薬剤評価用細胞培養物 | |
| WO2021251419A1 (ja) | 内耳有毛細胞の製造方法、薬剤の評価方法、及び細胞分化誘導用組成物 | |
| Okubo et al. | Fabrication of three-dimensional lacrimal gland-like tissue organoids from human pluripotent stem cells | |
| CN116731961A (zh) | 一种第三咽囊内胚层的培养方法及应用 | |
| KR20240131080A (ko) | 배외내배엽 줄기세포의 배양용 배지 조성물 | |
| CN117242170A (zh) | 在微载体上重编程体细胞 | |
| Obrtlíková | Differentiation of Human Embryonic Stem Cells into Endothelial and Smooth Muscle Cells as a Model for Vascular Development | |
| Karamil | Soft tissue stiffness influences early commitment of mouse embryonic stem cells towards endodermal lineage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170407 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170407 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20170407 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20170426 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170707 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170829 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170919 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6218152 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |